Truist Raises PT on Amneal Pharmaceuticals (AMRX) to $15 From $14

Group 1 - Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) is recognized as one of the best performing pharmaceutical stocks in 2025, with a price target raised to $15 from $14 by Truist while maintaining a Buy rating [1] - The U.S. Food and Drug Administration approved Amneal Pharmaceuticals' Biologics Licensing Applications for two biosimilars, Boncresa™ and Oziltus™, which reference Prolia® and XGEVA® respectively [2] - The addition of these two denosumab biosimilars expands Amneal's portfolio to five commercial biosimilars, enhancing its position in the biosimilars market [3] Group 2 - Amneal Pharmaceuticals operates in various segments including Generics, Specialty, and AvKARE, and offers a diverse product portfolio that includes biosciences, specialty drugs, and generics [4]